相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
Ali Ghasemzadeh et al.
CLINICAL CANCER RESEARCH (2016)
Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
Omar A. Ali et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor trial
L. Y. Dirix et al.
CANCER RESEARCH (2016)
PD-L1 expression in tumour buds of colorectal carcinoma
Friedrich Prall et al.
HISTOPATHOLOGY (2016)
Prognostic significance of PD-L1 and PD-L2 in breast cancer
Mauricio Z. Baptista et al.
HUMAN PATHOLOGY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Latent Tuberculosis in Pregnancy: A Systematic Review
Isabelle Malhame et al.
PLOS ONE (2016)
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
H. R. Ali et al.
ANNALS OF ONCOLOGY (2015)
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney et al.
CLINICAL THERAPEUTICS (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
PD-L1 expression is common and indicates poor prognosis
Clemens Thoma
Nature Reviews Urology (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Gregory K. Pennock et al.
ONCOLOGIST (2015)
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
Ninh M. La-Beck et al.
PHARMACOTHERAPY (2015)
Prognostic value of programmed cell death-ligand I expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis
Anyuan Zhong et al.
ONCOTARGETS AND THERAPY (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
Matthew Weinstock et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper et al.
CLINICAL CANCER RESEARCH (2014)
Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy
Kim A. Reiss et al.
IMMUNOTHERAPY (2014)
First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
N. A. Rizvi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
The primary microbial pathogens associated with premature rupture of the membranes in China: A systematic review
Li-nan Zeng et al.
TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY (2014)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration
Jan P. Vandenbroucke et al.
INTERNATIONAL JOURNAL OF SURGERY (2014)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen
Jennifer M. Bordeaux et al.
PLOS ONE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
ANNALS OF INTERNAL MEDICINE (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Regulatory T cells: how do they suppress immune responses?
Shimon Sakaguchi et al.
INTERNATIONAL IMMUNOLOGY (2009)
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
C. A. Crane et al.
ONCOGENE (2009)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
The role of death receptor ligands in shaping tumor microenvironment
Theresa L. Whiteside
IMMUNOLOGICAL INVESTIGATIONS (2007)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis
S Duval et al.
BIOMETRICS (2000)
分享论文
